Bristol-Myers Squibb’s new dosing for cancer drug Opdivo gets FDA green light
The approval is for a supplemental Biologics Licence Application which updates the Opdivo (nivolumab) dosing schedule to include 480 mg infused every four weeks
Company
Bristol-Myers Squibb Co
NYSE:BMY
Bristol-Myers Squibb Co is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases.
79 stories · page 3 of 4
Bristol-Myers shares on the uptick after positive lung cancer trial results and market beating fourth quarter results
Its Opdivo and Yervoy cancer drug combination showed improved progression-free survival in patients with advanced lung cancer compared to chemotherapy in a Phase III trial
Bristol-Myers Squibb, Cirrus Logic, Arconic Inc, SYSCO and more - PRE-MARKET
We take a look at what's hot and what's not in pre-market deals in New York
Merck shares continue to rise after successful lung cancer trial
Results from a large-scale trial showed a combination of Merck’s Keytruda drug and an older type of chemotherapy helped newly-diagnosed cancer patients live longer and stop the disease from advancing
Bristol-Myers Squibb drops on surprise third quarter profits miss
Third quarter profits slumped to US$845mln or 51 cents per share from US$1.20bn or 72 cents a share in the year-earlier period
Halozyme Therapeutics stock to surge thanks to Bristol-Myers licensing deal
Halozyme gets US$105mln upfront plus milestone payments and a share of future revenues
Bristol Myers Squibb kidney cancer treatment meets endpoint of late-stage trial
The pharmaceutical company's combination treatment for renal cell carcinoma showed superior overall survival rates in previously untreated patients compared to chemotherapy
L Brands, Agilent Technologies, Bristol-Myers Squibb Co and more - AFTER HOURS
A first look at what happened after hours in the US market
Array Biopharma and Bristol Myers to work on colorectal cancer combo therapy
Array, MEK inhibitor, binimetinib, Bristol-Myers, immuno-oncology, Opdivo.
Bristol Myers Squibb buoyed by surge in sales of key drugs
Opdivo sales jumped by 60% in the three months to March
Bristol-Myers enters into two license deals with Biogen and Roche worth up to US$1.1bn
Bristol is licensing an experimental neurodegenerative disorder drug to Biogen and a Duchenne muscular dystrophy treatment to Roche
CytomX Therapeutics shoots higher as it's set for US$200mln upfront payment from Bristol-Myers Squibb
CytomX will also be eligible to receive up to US$448mln in milestone payments, as well as royalty payments, if development, regulatory and sales targets are met.
Exelixis to start new combo cancer trials with Bristol-Myers and Roche
Exelisis will combine Cabometyx with blockbuster PD-1 immunotherapy drug Opdivo (nivolumab)
Pharmaxis enters 2017 cashed up as shares strengthen
Pharmaxis is becoming a more enticing target for drug acquisition and partnerships.
Pharmaxis on track for multi-million euro milestone payment
The commencement of the trial will trigger a milestone payment.
US stocks trend higher, but unfazed by Trump’s damp inauguration
US stocks closed higher on Friday, but little changed following Donald Trump’s first speech as President
Bristol-Myers shares hit by new lung cancer disappointment
It made the decision about the Opdivo and Yervoy combination after assessing the data available
US shares end up as oil investors crowd out depressed pharma post-Trump speech
US shares ended higher on Wednesday, as energy investors shrugged off a jump in US oil stocks, and markets took a sanguine view of President-elect Donald Trump’s first speech since he won the November election
Bristol-Myers announces results for Opdivo
Bristol-Myers Squibb Company on Tuesday announced updated results for Opdivo monotherapy
US stocks close lower as a bonds rout indicates Dec rate hike
US stocks ended lower, swinging from initial gains amid mixed earnings results, as a global bonds sell-off ensued on growing expectations for a Dec rate hike